RxDoctor Payments Data

Elizabeth Welch, NP

Family · Laurel, MSNPI 1588119176

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 84 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$439
  • Lilly USA, LLC$312
  • AstraZeneca$149
  • Novo Nordisk$101
  • GSK$92
  • Boehringer Ingelheim$83
  • plus $125 from 4 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,301 in reported general payments places this provider in the 70th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$61,006
Medicare patients
226
Services billed
2,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide141$163,814
OzempicSemaglutide99$91,029
JardianceEmpagliflozin85$88,665
FarxigaDapagliflozin Propanediol122$79,822
LinzessLinaclotide69$41,269
TrulicityDulaglutide26$26,119
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$25,784
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$22,031
Tresiba Flextouch U-100Insulin Degludec40$19,792
JanuviaSitagliptin Phosphate29$18,715
MyrbetriqMirabegron30$17,585
XareltoRivaroxaban17$15,582
JanumetSitagliptin Phos/Metformin Hcl15$15,217
EliquisApixaban19$14,729
Tresiba Flextouch U-200Insulin Degludec16$10,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$312$189,933167 claims
AstraZenecaFarxiga, Breztri Aerosphere$149$101,853155 claims
Boehringer IngelheimJardiance, Combivent Respimat$83$95,569100 claims
Novo NordiskOzempic$101$91,02999 claims
AbbVieLinzess, Synthroid$439$43,250116 claims
MerckJanuvia, Janumet$28$33,93344 claims
GSKTrelegy Ellipta, Breo Ellipta$92$32,34245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,007 family providers in Mississippi.

Other family in Laurel

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →